A pharmaceutical composition contains tizoxanide and choline hydroxide, a choline salt of tizoxanide and crystal form thereof. A mixture of tizoxanide and choline hydroxide, or a salt thereof and crystal form of the salt significantly improve the solubility and bioavailability of tizoxanide, and exhibits favorable effects in drugs for treating viruses, fibrosis, bacteria, tumors and intestinal parasites.

Provided are: a water-soluble composition which has excellent storage stability and is adaptable to a wide range of light sources and capable of forming a highly fine pattern; a method of producing a cured product of the same; a cured product of the same; and an acylphosphinate. The water-soluble composition contains: an acylphosphinate (A) represented by Formula (I) below, wherein X.sup.1 represents an aryl group having 6 to 15 carbon atoms; X.sup.2 represents a linear alkyl group having 1 to 8 carbon atoms or the like; A.sup.m+ represents an alkali metal ion or the like; and m represents a number of 1 to 3; and a compound (B) having a group represented by Formula (II) below, wherein R.sup.1 represents a hydrogen atom or the like; Z.sup.1 represents an oxygen atom or the like; R.sup.2 represents a hydrogen atom or the like; Z.sup.2 represents an alkylene group having 1 to 6 carbon atoms; n represents a number of 0 to 30; * means a bond; and, when the compound (B) has plural groups represented by Formula (II), plural R.sup.1′s, Z.sup.1′s, Z.sup.2′s and n's are each optionally the same or different. ##STR00001##

Provided are: a water-soluble composition which has excellent storage stability and is adaptable to a wide range of light sources and capable of forming a highly fine pattern; a method of producing a cured product of the same; a cured product of the same; and an acylphosphinate. The water-soluble composition contains: an acylphosphinate (A) represented by Formula (I) below, wherein X.sup.1 represents an aryl group having 6 to 15 carbon atoms; X.sup.2 represents a linear alkyl group having 1 to 8 carbon atoms or the like; A.sup.m+ represents an alkali metal ion or the like; and m represents a number of 1 to 3; and a compound (B) having a group represented by Formula (II) below, wherein R.sup.1 represents a hydrogen atom or the like; Z.sup.1 represents an oxygen atom or the like; R.sup.2 represents a hydrogen atom or the like; Z.sup.2 represents an alkylene group having 1 to 6 carbon atoms; n represents a number of 0 to 30; * means a bond; and, when the compound (B) has plural groups represented by Formula (II), plural R.sup.1′s, Z.sup.1′s, Z.sup.2′s and n's are each optionally the same or different. ##STR00001##

The invention relate to use of aqueous solution of organic ammonium carboxylate of formula (I): [NR.sup.1R.sup.2R.sup.3R.sup.4].sup.+n[R.sup.5(COO)].sup.−n, in which R.sup.1, R.sup.2, and R.sup.3 are selected from the group composing of hydrogen and methyl, R.sup.4 is a C.sub.1-C.sub.4-alkyl substituted with a hydroxyl group, R.sup.5 is hydrogen or methyl and n is 1, as a mist or drops in preventing dusting of fine material and in lowering the freezing point of said aqueous solution on the surface of said fine material or on the surface of dust particles obtained from said fine material by spraying said mist or drops onto fine material or onto dust particles obtained from said fine material to neutralize negatively charged dust particles or by changing negatively charged dust particles into positively charged dust particles, wherein said fine material is selected from the group composing of sand, crushed stone, stone powder, crushed expanded clay, or crushed expanded clay aggregate, crushed cement or concrete, cement or concrete powder, chopped organic material, minerals and metal powder.

The present invention relates to pharmaceutically acceptable water soluble salts of aldose reductase inhibitors, 2-(8-oxo-7-((5-trifluromethyl)-1H-benzo[d]imidazol-2-yl)methyl)7,8-dihydropyrazin[2,3-d]pyridazin-5-yl)acetic acid and [4-oxo-(5-trifluoromethyl-benzothaiazol-2-yl)methyl)-3,4-dihydro-phthalazin-1-yl]-acetic acid (also known as zopolrestat), pharmaceutical compositions thereof and methods of treating diabetic complications in mammals comprising administering to mammals these salt and compositions.

The present invention relates to pharmaceutically acceptable water soluble salts of aldose reductase inhibitors, 2-(8-oxo-7-((5-trifluromethyl)-1H-benzo[d]imidazol-2-yl)methyl)7,8-dihydropyrazin[2,3-d]pyridazin-5-yl)acetic acid and [4-oxo-(5-trifluoromethyl-benzothaiazol-2-yl)methyl)-3,4-dihydro-phthalazin-1-yl]-acetic acid (also known as zopolrestat), pharmaceutical compositions thereof and methods of treating diabetic complications in mammals comprising administering to mammals these salt and compositions.

A deep eutectic solvent consisting of (2-hydroxyethyl) trimethyl ammonium chloride and dithiothreitol in a molar ratio of from 1:2 to 1:3 and from 0% to 10% co-solvent, and methods of enzymatic production of polypeptides using the deep eutectic solvent.

The present invention discloses a process for preparing a functionalized choline chloride ionic liquid as defined in formula (I), and thereof use in an electrochemical energy storage device, as an electrolyte solution or an additive for a lithium ion battery and a supercapacitor. The ionic liquid electrolyte material has better biocompatibility, flame retardance, high ionic conductivity, low viscosity, and wide electrochemical window. ##STR00001## wherein R.sup.1 is selected from the group consisting of: (CH.sub.2═CH—(CH.sub.2).sub.n)—, CN(CH.sub.2).sub.n—, or R.sup.2.sub.3Si—; R.sup.2 is selected from CH.sub.3—(CH.sub.2).sub.m—, n is an integer selected from 1 to 3, m is an integer selected from 0 to 2; or one of R.sup.2 is (CH.sub.3).sub.3Si—O—. Anion A in Formula I is selected from the group consisting of: Cl.sup.−, Br.sup.−, I.sup.−, BF.sub.4.sup.−, NO.sub.3.sup.−, SO.sub.4.sup.2−, CF.sub.3COO.sup.−, CF.sub.3SO.sub.3.sup.−, (CF.sub.3SO.sub.2).sub.2N.sup.−, PF.sub.6.sup.−, BF.sub.2C.sub.2O.sub.4.sup.−, or B(C.sub.2O.sub.4).sub.2.sup.−.

The present invention discloses a process for preparing a functionalized choline chloride ionic liquid as defined in formula (I), and thereof use in an electrochemical energy storage device, as an electrolyte solution or an additive for a lithium ion battery and a supercapacitor. The ionic liquid electrolyte material has better biocompatibility, flame retardance, high ionic conductivity, low viscosity, and wide electrochemical window. ##STR00001## wherein R.sup.1 is selected from the group consisting of: (CH.sub.2═CH—(CH.sub.2).sub.n)—, CN(CH.sub.2).sub.n—, or R.sup.2.sub.3Si—; R.sup.2 is selected from CH.sub.3—(CH.sub.2).sub.m—, n is an integer selected from 1 to 3, m is an integer selected from 0 to 2; or one of R.sup.2 is (CH.sub.3).sub.3Si—O—. Anion A in Formula I is selected from the group consisting of: Cl.sup.−, Br.sup.−, I.sup.−, BF.sub.4.sup.−, NO.sub.3.sup.−, SO.sub.4.sup.2−, CF.sub.3COO.sup.−, CF.sub.3SO.sub.3.sup.−, (CF.sub.3SO.sub.2).sub.2N.sup.−, PF.sub.6.sup.−, BF.sub.2C.sub.2O.sub.4.sup.−, or B(C.sub.2O.sub.4).sub.2.sup.−.

A quaternary ammonium salt of formula wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is independently selected from an optionally substituted alkyl, alkenyl or aryl group having less than 8 carbon atoms and R.sup.5 is hydrogen or an optionally substituted hydrocarbyl group.

##STR00001##